One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
China Biologic Products Holdings, Inc. logo
China Biologic Products Holdings, Inc. CBPO

China Biologic Products Holdings, Inc. Financial Ratios 2020-2011 | CBPO

Brief overview of China Biologic Products Holdings, Inc.'s valuation multiples

This overview follows the five latest available observations from 2016 through 2020.

The latest available valuation ratios are P/E 29.92x (median 29.92x), EV/EBITDA 17.43x (median 17.43x), P/S 8.69x (median 8.69x). The multiple basket looks neutral against its history, differing from median levels by roughly 0%.

The inverse P/E implies an earnings yield of 3.3%. This is not a dividend yield, but current earnings relative to market price.

Current measures of operating quality are ROE 7.3%, ROA 6.7%, ROCE 9.2%. Business quality is below comfortable levels on current returns. Better margins or turnover are needed.

Price, earnings and growth produce a PEG of 2.73x. A high value reduces the cushion if growth slows.

Conclusion

China Biologic Products Holdings, Inc. trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.

Annual Financial Ratios China Biologic Products Holdings, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
29.9 32.4 21.6 32.7 29.0 36.9 23.5 14.0 11.2 13.3

P/S

8.7 8.9 5.9 6.0 8.9 11.1 6.8 3.8 2.7 1.6

EV/EBITDA

17.4 22.8 14.3 13.5 18.3 22.2 14.1 7.0 4.6 2.5

PEG

2.73 114.53 0.45 -0.89 2.53 1.91 0.6 0.76 0.08 -0.29

P/B

2.2 2.5 1.5 3.3 5.8 7.0 6.0 2.5 2.0 1.4

P/CF

19.2 21.9 41.1 34.8 42.1 57.5 23.2 14.5 11.8 8.1

ROE %

7.32 7.82 6.94 10.23 20.11 19.07 25.76 17.96 17.57 10.16

ROA %

6.74 7.16 6.37 8.40 17.32 16.15 15.87 13.52 14.54 7.31

ROCE %

9.21 9.00 7.74 19.10 27.08 27.63 34.08 25.54 28.29 31.47

DSO

105.9 72.7 97.8 121.4 36.3 31.0 29.1 31.0 22.1 46.1

DIO

530.4 523.9 605.0 609.4 460.3 433.3 462.1 494.0 469.5 565.8

DPO

9.2 13.1 28.4 22.0 18.1 33.2 22.0 24.8 18.0 39.6

All numbers in USD currency

Multiples are an important financial analysis tool for the company China Biologic Products Holdings, Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Auris Medical Holding Ltd. Auris Medical Holding Ltd.
EARS
- -1.77 % $ 39.2 M bermudaBermuda
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
- 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
- 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
- - $ 6.81 B britainBritain
22nd Century Group 22nd Century Group
XXII
$ 0.32 -19.83 % $ 58.9 K usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
- - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
- - $ 256 M canadaCanada
argenx SE argenx SE
ARGX
$ 926.42 -1.66 % $ 56.8 B niderlandNiderland
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 2.33 -7.25 % $ 19.8 M usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
$ 21.01 -4.16 % $ 23 B chinaChina
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
- -2.54 % $ 57.2 M usaUSA
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
$ 1.37 0.74 % $ 98.5 M usaUSA
Zoetis Zoetis
ZTS
$ 78.81 -2.47 % $ 34.9 B usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
- -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
- -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
- -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
- - $ 1.77 B usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 1.47 -4.55 % $ 2.5 M usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
- - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
- - $ 1.94 B canadaCanada
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
- - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
- - $ 10.9 B usaUSA
Zogenix, Inc. Zogenix, Inc.
ZGNX
- -4.97 % $ 664 M usaUSA
Yunhong International Yunhong International
ZGYH
- 0.10 % $ 92.2 M chinaChina
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
- -7.58 % $ 264 M usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 3.71 -1.72 % $ 1.19 B usaUSA
Vericel Corporation Vericel Corporation
VCEL
$ 57.41 -1.46 % $ 2.89 B usaUSA
Vir Biotechnology Vir Biotechnology
VIR
$ 8.37 -5.64 % $ 1.16 B usaUSA
Veracyte Veracyte
VCYT
$ 25.08 0.16 % $ 1.97 B usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
$ 24.72 -4.35 % $ 2.79 B usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
$ 3.44 -6.27 % $ 203 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.16 -12.33 % $ 6.09 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 1.52 -5.9 % $ 89.2 M usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 2.74 -5.03 % $ 29.2 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
$ 2.56 -6.07 % $ 432 M singaporeSingapore
XBiotech XBiotech
XBIT
$ 1.75 4.17 % $ 53.4 M usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
$ 1.37 -7.43 % $ 922 M israelIsrael
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.15 -35.42 % $ 2.11 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 13.18 -1.2 % $ 3.14 B usaUSA
Exicure Exicure
XCUR
$ 0.96 -7.24 % $ 6.05 M usaUSA
Xencor Xencor
XNCR
$ 33.48 -1.56 % $ 2.49 B usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 3.24 -5.55 % $ 710 M britainBritain
Daré Bioscience Daré Bioscience
DARE
$ 0.41 -9.93 % $ 4.58 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
$ 0.92 -9.07 % $ 109 M usaUSA
Greenwich LifeSciences Greenwich LifeSciences
GLSI
$ 19.09 -3.54 % $ 258 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 91.28 -1.89 % $ 10.9 B usaUSA
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
$ 13.18 -2.04 % $ 11.3 B chinaChina
Aptorum Group Limited Aptorum Group Limited
APM
- - $ 5.72 M chinaChina
iBio iBio
IBIO
$ 0.83 3.01 % $ 86.4 M usaUSA